Literature DB >> 9002124

Use of fluoroquinolones as prophylactic agents in patients with neutropenia.

C C Patrick1.   

Abstract

BACKGROUND: The use of fluorinated quinolone antibiotics to selectively decontaminate the gastrointestinal tract is a reasonable alternative to prevent infection in neutropenic patients. The fluoroquinolones represent ideal antibiotics with which to achieve the principles of selective decontamination by allowing colonization of anaerobes to inhibit the adherence, colonization and proliferation of potentially pathogenic aerobic flora.
OBJECTIVE: This report describes the prophylactic use of fluoroquinolones in neutropenic patients.
RESULTS: The majority of studies of fluoroquinolone prophylaxis in neutropenic patients have shown a reduction in documented Gram-negative bacterial infections. However, Gram-positive infections, particularly those with viridans streptococci, present a major impediment to the use of single agent prophylaxis with a quinolone.
CONCLUSION: Prophylaxis with fluoroquinolones in neutropenic patients was found to be advantageous, but it must be balanced against the risk of Gram-positive infections and the potential for antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002124     DOI: 10.1097/00006454-199701000-00038

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe.

Authors:  A van Belkum; M C Vos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Malini Surapaneni; Kamya Sankar; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Pranatharthi Chandrasekar; Joseph P Uberti
Journal:  Support Care Cancer       Date:  2017-04-02       Impact factor: 3.603

3.  Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis.

Authors:  R M Prabhu; K E Piper; M R Litzow; J M Steckelberg; R Patel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 4.  Fluoroquinolones in paediatrics.

Authors:  D Gendrel; F Moulin
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

Authors:  Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2011-04-20       Impact factor: 3.167

Review 6.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

7.  Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.

Authors:  Dong Gun Lee; Su Mi Choi; Jung Hyun Choi; Jin Hong Yoo; Yoon Hee Park; Yoo Jin Kim; Seok Lee; Chang Ki Min; Hee Je Kim; Dong Wook Kim; Jong Wook Lee; Woo Sung Min; Wan Shik Shin; Chun Choo Kim
Journal:  Korean J Intern Med       Date:  2002-03       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.